Report Interpretation

FAQs on ImpriMed's service reports

Are patients on drug treatments when we look at the progression-free survival graph?

Yes, probably the patient would be taking some form of drug treatment when we look at the progression-free survival graph. Basically, the patients were not treatment free at the time.

Is there any reason to believe that submitting another sample to you would provide any additional information or possible changes in treatment protocols now that we are almost 4 months into the treatment plan?

We would suggest you submit another FNA and blood samples to us WHEN the patient's lymphoma relapses. Relapse of lymphoma means that the cancer develops a resistance to certain chemo drugs in use. When this happens, the relapsed cancer cells are usually different from the ones investigated in the naive status, which led to different drug response predictions to the tested drugs. Therefore, it would be better to get new tumor samples and find out what are the new preferred drugs and which of the used drugs still remain effective or became resistant for the relapsed lymphoma. However, the best scenario is to maintain clinical remission for as long a period of time so that you don’t have to order another service from us! If a second service is needed, we offer a 50% discount for returning patients.

Can we select non-MDR substrate drugs for known or suspected MDR dogs?

Yes, you can select non-MDR1 drugs when indicating your drug priorities, but the final report will also include all drugs.

Is it wise to eliminate a certain chemotherapy drug based on the test results or should there be other factors that need to be considered in this decision?

We do not recommend using ImpriMed's predictions to rule out treatment options. The company's artificial intelligence is optimized to give high positive predictive value to help you find drugs with the highest likelihood of producing positive clinical outcomes. For the bests results, our predictions should be used in conjunction with expert knowledge from a skilled oncologist.

What is the simulated dosing for a certain drug? MTD(maximum tolerated dosing) or metronomic?

Our models don't differentiate between different types of dosing, so they can be viewed as outcomes for standard clinical practice. For instance, if MTD is more common in practice, the models may more closely reflect MTD.

Still have a question that needs a little human touch?